Sign in
CompletedNo phase

Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor

Key facts

Who runs it
University of Copenhagen
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
25 people enrolled
Started
13 Aug 2019
Ended
28 Nov 2023
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • GIP-A
  • Placebo
Record updated
29 November 2023

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Patients under clinical investigation of acromegaly disease with normal kidney function, liver function and hemoglobin levels

Who cannot take part

  • Medication for acromegaly, adenectomy, liver disease, uncontrolled anemia, severe heart disease, uncontrolled high blood pressure (>170/100 mmHg), current pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma

The 2 groups in the trial

  • GIP-AOther group

    Infusion of GIP-A alone as a study tool.

  • PlaceboPlacebo, for comparison

    Saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor
Record updated
29 November 2023